PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32860796-5	2020	Using various biochemical assays, the 7-methoxycoumarin derivative N13 was identified as a potent inhibitor of BRD4 BD2.	2-{3-[3-(1h-Benzimidazol-2-Yl)-1h-Indazol-6-Yl]-1h-Pyrazol-5-Yl}-N-(3-Fluorophenyl)acetamide	67-70	bromodomain containing 4	Homo sapiens	111-115	
32860796-6	2020	Compared with the well-known BRD4 inhibitor JQ1, N13 exhibited higher potency against BRD4 BD2 and much higher specificity for BRD4 BD2 over BRD4 BD1.	2-{3-[3-(1h-Benzimidazol-2-Yl)-1h-Indazol-6-Yl]-1h-Pyrazol-5-Yl}-N-(3-Fluorophenyl)acetamide	49-52	bromodomain containing 4	Homo sapiens	29-33	
32860796-6	2020	Compared with the well-known BRD4 inhibitor JQ1, N13 exhibited higher potency against BRD4 BD2 and much higher specificity for BRD4 BD2 over BRD4 BD1.	2-{3-[3-(1h-Benzimidazol-2-Yl)-1h-Indazol-6-Yl]-1h-Pyrazol-5-Yl}-N-(3-Fluorophenyl)acetamide	49-52	bromodomain containing 4	Homo sapiens	86-90	
32860796-6	2020	Compared with the well-known BRD4 inhibitor JQ1, N13 exhibited higher potency against BRD4 BD2 and much higher specificity for BRD4 BD2 over BRD4 BD1.	2-{3-[3-(1h-Benzimidazol-2-Yl)-1h-Indazol-6-Yl]-1h-Pyrazol-5-Yl}-N-(3-Fluorophenyl)acetamide	49-52	bromodomain containing 4	Homo sapiens	86-90	
32860796-6	2020	Compared with the well-known BRD4 inhibitor JQ1, N13 exhibited higher potency against BRD4 BD2 and much higher specificity for BRD4 BD2 over BRD4 BD1.	2-{3-[3-(1h-Benzimidazol-2-Yl)-1h-Indazol-6-Yl]-1h-Pyrazol-5-Yl}-N-(3-Fluorophenyl)acetamide	49-52	bromodomain containing 4	Homo sapiens	86-90	
32860796-7	2020	Additionally, N13 inhibited the proliferation of two kinds of BRD4-overexpressing melanoma cell lines.	2-{3-[3-(1h-Benzimidazol-2-Yl)-1h-Indazol-6-Yl]-1h-Pyrazol-5-Yl}-N-(3-Fluorophenyl)acetamide	14-17	bromodomain containing 4	Homo sapiens	62-66	
32860796-9	2020	To our knowledge, N13 is the first 7-methoxybicoumarin-based BRD4 BD2 inhibitor described to date and may function as a new scaffold for developing more specific and potent therapeutic agents against BRD4 BD2.	2-{3-[3-(1h-Benzimidazol-2-Yl)-1h-Indazol-6-Yl]-1h-Pyrazol-5-Yl}-N-(3-Fluorophenyl)acetamide	18-21	bromodomain containing 4	Homo sapiens	61-65	
32860796-9	2020	To our knowledge, N13 is the first 7-methoxybicoumarin-based BRD4 BD2 inhibitor described to date and may function as a new scaffold for developing more specific and potent therapeutic agents against BRD4 BD2.	2-{3-[3-(1h-Benzimidazol-2-Yl)-1h-Indazol-6-Yl]-1h-Pyrazol-5-Yl}-N-(3-Fluorophenyl)acetamide	18-21	bromodomain containing 4	Homo sapiens	200-204